- Home
- CLIK vs BLRX Comparison
CLIK vs BLRX Comparison
Compare CLIK & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLIK
- BLRX
- Stock Information
- Founded
- CLIK 2017
- BLRX 2003
- Country
- CLIK Hong Kong
- BLRX Israel
- Employees
- CLIK N/A
- BLRX N/A
- Industry
- CLIK
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CLIK
- BLRX Health Care
- Exchange
- CLIK NYSE
- BLRX Nasdaq
- Market Cap
- CLIK 16.9M
- BLRX 15.3M
- IPO Year
- CLIK 2024
- BLRX 2011
- Fundamental
- Price
- CLIK $0.45
- BLRX $4.24
- Analyst Decision
- CLIK
- BLRX Strong Buy
- Analyst Count
- CLIK 0
- BLRX 2
- Target Price
- CLIK N/A
- BLRX $19.00
- AVG Volume (30 Days)
- CLIK 806.2K
- BLRX 2.1M
- Earning Date
- CLIK 02-14-2025
- BLRX 08-14-2025
- Dividend Yield
- CLIK N/A
- BLRX N/A
- EPS Growth
- CLIK N/A
- BLRX N/A
- EPS
- CLIK 0.07
- BLRX N/A
- Revenue
- CLIK $6,051,074.00
- BLRX $22,340,000.00
- Revenue This Year
- CLIK N/A
- BLRX N/A
- Revenue Next Year
- CLIK N/A
- BLRX N/A
- P/E Ratio
- CLIK $6.73
- BLRX N/A
- Revenue Growth
- CLIK 36.12
- BLRX 91.68
- 52 Week Low
- CLIK $0.16
- BLRX $2.30
- 52 Week High
- CLIK $4.39
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- CLIK N/A
- BLRX 47.70
- Support Level
- CLIK N/A
- BLRX $4.34
- Resistance Level
- CLIK N/A
- BLRX $6.59
- Average True Range (ATR)
- CLIK 0.00
- BLRX 0.69
- MACD
- CLIK 0.00
- BLRX -0.14
- Stochastic Oscillator
- CLIK 0.00
- BLRX 13.28
About CLIK CLICK HOLDINGS LIMITED
Click Holdings Ltd is a human resources solutions provider, specializing in offering comprehensive human resources solutions. It is focused on talent sourcing and the provision of temporary and permanent personnel to customers and also in placing professional accountants and company secretaries, registered nurses and healthcare workers as well as other blue-collar workers, for direct hire and contract staffing roles. The Company operates in three segments, 1) professional solution services, 2) nursing solution services and 3) logistic and other solution services. Maximum revenue is generated from Professional solution services and Hong Kong.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.